GYRE THERAPEUTICS, INC. quarterly report, Q2 FY2012

Business context and reporting period

Registrant discrepancy: The supplied filing is Targacept, Inc.’s Form 10-Q for the quarter ended June 30, 2012; it is not identified as Gyre Therapeutics, Inc. The financial statements are unaudited.

Targacept was a clinical-stage biopharmaceutical company developing neuronal nicotinic receptor therapeutics. Its portfolio included TC-5619 and AZD3480 in Phase 2 studies, with AZD3480 and AZD1446 subject to a cognitive-disorders collaboration with AstraZeneca.

Financial performance and position

Amounts below are in millions of dollars except per-share data.

• Q2 operating margin was approximately 42%; first-half operating margin was approximately 29%.
• First-half operating cash flow was a use of $42.2 million, versus a use of $45.1 million a year earlier. Cash and cash equivalents declined $35.6 million in the first half.
• At June 30, cash, cash equivalents and marketable securities totaled $205.9 million. Total debt was approximately $2.4 million; total liabilities were $16.3 million.
• At June 30, total assets were $212.6 million, stockholders’ equity was $196.4 million, and accumulated deficit was $210.2 million.

Material changes versus prior comparable periods

• Q2 revenue rose $12.9 million year over year, largely because the company accelerated recognition of the AstraZeneca TC-5214 upfront payment after development plans changed. The $200 million upfront payment was fully recognized by June 30, 2012; this revenue recognition was not equivalent to new-period cash receipts.
• First-half revenue decreased $3.2 million year over year, as 2011 included recognition of deferred GlaxoSmithKline revenue and TC-5619-related payments that were no longer recurring.
• Research and development expense fell $7.7 million in Q2 and $13.4 million for the first half, mainly as TC-5214 activity wound down and the company completed two TC-6987 Phase 2 trials. General and administrative expense increased, including executive departure-related compensation.
• A $2.3 million restructuring charge was recorded in the first half. The April 2012 workforce reduction eliminated 65 positions, approximately 46% of staff.

Outlook, commentary, risks and unusual items

• Management expected existing capital resources to fund operations through at least the end of 2015, excluding potential AstraZeneca milestone payments. It cautioned that plans could change and additional capital might be needed sooner.
• Management expected revenue in the remainder of 2012 to decrease substantially after full recognition of the TC-5214 upfront payment. It expected full-year R&D expense to decline from 2011, while continuing significant spending on TC-5619 Phase 2 trials and the AZD3480 Alzheimer’s study.
• AstraZeneca terminated the TC-5214 agreement effective in late May 2012. The company remained responsible for 20% of certain final program costs. The Phase 3 results did not support pursuing a regulatory filing for TC-5214 as an adjunct treatment, and the switch-monotherapy Phase 2b trial was discontinued.
• Potential future funding under the cognitive-disorders agreement depended on uncertain milestones. The filing said no AZD3480 or AZD1446 milestone was expected to be achievable in 2012 based on projected activities and timelines; AZD1446 was not in an active clinical trial.
• Key risks included clinical and regulatory uncertainty, reliance on AstraZeneca for partnered programs, the impact of workforce and executive departures, and uncertainty over future financing and collaborations. The filing also disclosed a $506,000 estimated former-CEO severance obligation and ongoing discussions about renewal of a facility lease expiring July 31, 2012.
• Management reported disclosure controls were effective as of quarter-end and no material change in internal control over financial reporting occurred during the quarter.

Important facts for investors to verify

• Confirm the issuer identity: the supplied filing names Targacept, Inc., not Gyre Therapeutics, Inc.
• Assess the sustainability of reported earnings, given that TC-5214 deferred-revenue recognition materially supported 2012 revenue and ended in Q2.
• Track cash burn, the stated runway through at least 2015, and any changes in spending plans or financing needs.
• Verify clinical progress and outcomes for TC-5619 and AZD3480, and AstraZeneca’s development decisions and any milestone prospects for AZD3480 or AZD1446.
• Monitor final TC-5214 wind-down costs, restructuring effects, executive transitions, and the facility lease renewal.